QUECTEL-WIRELESS
27.3.2024 14:01:35 CET | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, has made further additions to its comprehensive range of antennas for IoT devices and deployments. The latest launches include the YEMN016AA and YEMN017AA 5G 5-in-1 combination antennas, the YECN001J1A and YECT000WBA external 5G antennas and the YEGB000Q1A and YEGN000Q1A active GNSS L1 and L5 antennas.
“We are thrilled to expand our product line with antennas that offer superior performance and meet the unique needs of our IoT customers,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “Quectel consistently enhances its diverse portfolio to precisely address the unique requirements of our clients' deployments and applications, offering unparalleled performance and adaptability, and these antennas add to that portfolio.”
The YEMN016AA is a 5G and global navigation satellite systems (GNSS) 5-in-1 antenna measuring 204.4mm x 86.7mm x 32mm. This ultra-wide-band 5G/4G antenna provides broad coverage from 600–6,000MHz whilst offering backward-compatibility to support 3G and 2G networks as well as LTE Cat-M and narrowband IoT (NB-IoT). The antenna is available with connection via five cable lengths from 300–5,000 mm, terminated with SMA connectors. This low profile, screw mount omnidirectional antenna, ideal for applications where the antenna is required to be discrete, is easy to install with maximum durability assured thanks to its IP69K PC KIBILAC® ASA enclosure. It is compatible with Quectel's RM520x Series modules.
The Quectel YEMN017AA is a 5G screw mount 5-in-1 antenna puck optimized for 5G and 4G networks. With a diameter of 103.5mm and height of 42.5mm, the antenna can integrate a variety of antennas, such as 5G, 4G, GNSS and Wi-Fi antennas. Available with multiple mounting options including screw, pole, wall, magnetic, adhesive and others, the antenna box supports multiple connector types and cable lengths and is designed to offer a more flexible and reliable high-performance antenna for outdoor applications.
Quectel has also added the YECN001J1A and YECT000WBA external 5G antennas to its portfolio. Both antennas cover the 5G NR Sub-6 GHz frequency bands and are compatible with 4G, 3G, 2G and LPWA bands. Featuring high efficiency and gain, both offer an ideal omni-directional antenna solution to ensure high-speed data transmission. Ideal for a diversity of wireless communication devices such as routers, outdoor equipment and real-time monitoring equipment, the antennas feature a diameter of 40.6mm and height of 104mm. The antennas are both RoHS and REACH compliant and Quectel offers flexible installation with custom cable length and connector options.
For users prioritizing GNSS, Quectel has introduced the YEGB000Q1A and YEGN000Q1A active GNSS L1 and L5 antennas. Operating in the 1164-1189MHz and 1559-1606MHz frequency bands these antennas measure 62mm x 56mm x 23mm. The antennas support different installation or connection methods such as screw mount, adhesive mount, magnetic mount, internal cable, and external SMA. Customized connector types and cable lengths are provided according to requirements.
In common with all Quectel antennas, Quectel provides comprehensive antenna design support such as simulation, testing and manufacturing for custom antenna solutions to meet customers’ specific application needs. In addition, Quectel antennas can be pre-integrated with Quectel’s vast range of modules.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327795741/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom